Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2023 · 10-Q
Revenue$135.56M$135.56M−20.3% vs Q2 2022 Net Income-$831.00K-$831.00KN/M vs Q2 2022 EPS Diluted-$0.02-$0.02N/M vs Q2 2022 Operating Income-$17,587,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$19,033,000N/M Margins · derivedOperating margin-13.0%−19.6 pt vs Q2 2022
Net margin-0.6%−5.2 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 8, 2023 · 39 d after period end